Aime T. Franco, PhD, provides an overview of her discussion regarding the molecular landscape of pediatric patients with thyroid cancer at the 91st Annual Meeting of the American Thyroid Association.
Aime T. Franco, PhD, assistant professor and investigator with the Center for Childhood Cancer Research at Children's Hospital of Philadelphia, provides an overview of her discussion regarding the molecular landscape of pediatric patients with thyroid cancer at the 91st Annual Meeting of the American Thyroid Association.
According to Franco, the thyroid cancer space tends to be underrepresented in the research spectrum due to low mortality rates associated with the disease and available treatment options.
However, there is always more to be learned, especially in examining the differences between pediatric and adult patients with thyroid cancer.
Transcription:
0:08 | I plan to discuss some of the new findings we have looking at the genetic and molecular landscape of pediatric thyroid cancers, and how this has improved our understanding and lended insight into how pediatric tumors are similar, but also very dissimilar to adult tumors, how we can personalize and specialize our approach to our pediatric patients compared to our adult patients. But also, to get us to start thinking about the fact that pediatric patients become adult patients, and how is that going to change over their lifespan?
0:46 | We don't have all those answers yet, but I think this is something we need to start thinking about in the clinical spectrum. Not only the immediate diagnosis, but what are the long term repercussions and how do we start to think about pediatric thyroid cancer as a lifespan disease and not just something that happens only during childhood.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Dual Immunotherapy Clinically Active in Anaplastic Thyroid Cancer
December 23rd 2024A phase 2 trial found that dual immune checkpoint inhibition with nivolumab and ipilimumab shows promise in anaplastic thyroid cancer, but limited effectiveness in radioiodine refractory differentiated thyroid carcinoma.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More